Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01NS082120 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | NIH |
Not provided
Not provided
Not provided
Not provided
Treponema pallidum, the bacterium that causes syphilis, invades the central nervous system in about 40% of patients with syphilis. This happens early after infection. Patients with neuroinvasion are at risk of developing serious neurological complications, including vision or hearing loss, stroke and dementia. Because neuroinvasion can happen without symptoms, the only way to identify it is by performing a lumbar puncture (LP) to examine cerebrospinal fluid (CSF).The overall hypothesis to be tested in this study is that a strategy of immediate LP, followed by therapy based on CSF evaluation, results in better serological and functional outcomes in patients with syphilis who are at high risk for neuroinvasion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LP | Other | Participants undergo lumbar puncture for CSF evaluation |
|
| No LP | No Intervention | Participants do not undergo lumbar puncture and CSF is not examined. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lumbar puncture | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer | Decline in serum RPR titer by four-fold or to nonreactive at 6 months (+/- 4 weeks) in early syphilis or at 12 months (+/- 4 weeks) in late syphilis. This is the definition of treatment success according to the US Centers for Disease Control and Prevention guidelines. | 6-12 months +/- 4 weeks |
| Time to Improvement in Performance on CogState Battery. | Assessment of cognitive impairment was based on age adjusted normative data from CogState and was categorized as none (all test scores > -1 standard deviation [SD] of normative data), mild impairment (two test scores < -1 SD, or one test score < -2 SD), moderate impairment (two test scores < -2 SD) or severe impairment (three test scores < -2 SD). Participants were categorized as improved if they had any impairment at study entry and improved by at least one category. | 6-12 months +/- 4 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Individuals who are unwilling to be randomized can choose LP or no LP. Eligibility criteria for these individuals are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christina M Marra, MD | University of Washington | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Washington Harborview Medical Center | Seattle | Washington | 98104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
The protocol section asks how many participants were enrolled. 219 unique participants were enrolled, but 12 had two enrollments. Thus there are 231 enrollment visits.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Randomized, Lumbar Puncture (LP) | Randomized to lumbar puncture (LP) arm |
| FG001 | Reenrolled, Randomized, LP | Randomised after a second enrollment, underwent LP |
| FG002 | Randomized, no LP | Randomized and did not undergo LP. Includes one person for whom LP was unsuccessful. |
| FG003 | Not Randomized, LP | Not randomized and underwent LP. |
| FG004 | Not Randomized, no LP | Not randomized and did not undergo LP. |
| FG005 | Reenrolled, Not Randomized, no LP | Not randomized during another episode of syphilis. Did not undergo LP. |
| FG006 | Reenrolled, Not Randomized, LP | Not randomized with a new episode of syphilis, underwent LP |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lumbar Puncture Group | Underwent lumbar puncture |
| BG001 | No Lumbar Puncture Group | Did not undergo lumbar puncture |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer | Decline in serum RPR titer by four-fold or to nonreactive at 6 months (+/- 4 weeks) in early syphilis or at 12 months (+/- 4 weeks) in late syphilis. This is the definition of treatment success according to the US Centers for Disease Control and Prevention guidelines. | Posted | Count of Participants | Participants | 6-12 months +/- 4 weeks |
|
One year
No difference
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Underwent Lumbar Puncture | Participants who underwent lumbar puncture. | 0 |
Not provided
Not provided
Inclusion of a non-randomized group introduces risk of bias; however, the groups were comparable with regard to neurosyphilis risk factors.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Christina Marra, MD | University of Washington | 206-744-3251 | cmarra@uw.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 16, 2020 | Dec 16, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D013587 | Syphilis |
| ID | Term |
|---|---|
| D014211 | Treponemal Infections |
| D013145 | Spirochaetales Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D013129 | Spinal Puncture |
| ID | Term |
|---|---|
| D001706 | Biopsy |
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | number in each category of race | Count of Participants | Participants | No |
|
| Serum Rapid Plasma Reagin test (RPR) titer | Titers are expressed as 2-fold dilutions: 1:1 1:2 1:4 1:8 and so on. | Median | Inter-Quartile Range | titer |
|
| Impaired on CogState Battery | The CogState is a computerized battery of neuropsychological tests. Assessment of cognitive impairment was based on age adjusted normative data, categorized as none (all test scores > -1 standard deviation [SD] of normative data), mild impairment (two test scores < -1 SD, or one test score < -2 SD), moderate impairment (two test scores < -2 SD) or severe impairment (three test scores < -2 SD). | Number | participants |
|
| OG001 |
| No Lumbar Puncture Group |
Did not undergo lumbar puncture. All were treated for uncomplicated syphilis. The number of participants with late syphilis was too small to allow for separate analysis of early and late stages. |
|
|
|
| Primary | Time to Improvement in Performance on CogState Battery. | Assessment of cognitive impairment was based on age adjusted normative data from CogState and was categorized as none (all test scores > -1 standard deviation [SD] of normative data), mild impairment (two test scores < -1 SD, or one test score < -2 SD), moderate impairment (two test scores < -2 SD) or severe impairment (three test scores < -2 SD). Participants were categorized as improved if they had any impairment at study entry and improved by at least one category. | Posted | Median | 95% Confidence Interval | months | 6-12 months +/- 4 weeks |
|
|
|
|
| Post-Hoc | Time to Decline in Performance on the CogState Battery | Participants were categorized as declined if they were not severely impaired at entry and declined by at least one category. The impairment categories are: none (all test scores > -1 standard deviation [SD] of normative data), mild impairment (two test scores < -1 SD, or one test score < -2 SD), moderate impairment (two test scores < -2 SD) or severe impairment (three test scores < -2 SD). | Time to decline in performance on the CogState battery by log rank test. | Posted | Median | 95% Confidence Interval | months | 6-12 months +/- 4 weeks |
|
|
|
|
| 62 |
| 0 |
| 62 |
| 0 |
| 62 |
| EG001 | Did Not Undergo Lumbar Puncture | Participants who did not undergo lumbar puncture. | 0 | 34 | 0 | 34 | 0 | 34 |
Not provided
Not provided
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D003933 | Diagnosis |
| D003943 | Diagnostic Techniques, Neurological |
| D011677 | Punctures |
| D013812 | Therapeutics |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |